{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:33:03Z","timestamp":1792902783230,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Krystal Biotech"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Dystrophic epidermolysis bullosa (EB) is a family of rare genetic dermatological conditions. Recent evidence indicated that in addition to its detrimental implications on patient health-related quality of life (HRQoL), there are substantial socioeconomic cost implications\n                      <jats:italic>,<\/jats:italic>\n                      especially regarding direct non-medical costs. This study aims to understand the burden of dystrophic EB (DEB) in Europe, using a primary EB patient-level dataset.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A bottom-up, cross-sectional, study design was adopted for non-institutionalised patients diagnosed with EB who received outpatient care across EU5 countries: France, Germany, Italy, Spain, and the United Kingdom. A prevalence-based approach was used to estimate resource utilisation from a societal perspective, including direct (medical and non-medical) and indirect costs for patients and caregivers. Patient and caregiver outcomes were obtained using the EQ-5D questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A sample of 91 DEB patients was analysed. Overall, average EU5 annual cost per patient was estimated at \u20ac53,359, ranging from \u20ac18,783 (France) to \u20ac79,405 (Germany). Average EU5 annual direct medical costs were estimated at \u20ac8357 (15.7% of total), ranging from \u20ac5658 (France) to \u20ac12,576 (Germany); average\u00a0direct non-medical costs were estimated at \u20ac41,353 (77.5% of total), ranging from \u20ac11,961 (France) to \u20ac57,000 (Germany); and average\u00a0indirect costs were estimated at \u20ac3649 (6.8% of total), ranging from \u20ac1025 (Italy) to \u20ac9930 (United Kingdom). Costs varied across patients with different disability but also between children and adults. The mean EQ-5D index score for adult DEB patients ranged between 0.304 (United Kingdom) and 0.541 (Germany), with an EU5\u00a0average of 0.456, whereas the mean EQ-5D visual analogue scale score ranged between 47.5 (Germany) and 70.0 (France), with an EU5\u00a0average of 61.9. Limitations included potential patient selection bias, recall bias, and exclusion of bandaging and related costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study revealed a substantial socioeconomic burden for DEB in Europe, attributable mostly to high direct non-medical costs, with the majority of patients requiring support from caregivers at home. Compared to the average economic burden of the overall EB patient population, costs for DEB patients are higher across all components of direct medical, direct non-medical and indirect costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02419-1","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T17:05:58Z","timestamp":1662483958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-4634","authenticated-orcid":false,"given":"A.","family":"Angelis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Mellerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kanavos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"issue":"6","key":"2419_CR1","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jaad.2008.02.004","volume":"58","author":"J-DMDMPHF Fine","year":"2008","unstructured":"Fine J-DMDMPHF, Eady RAJDFF, Bauer EAMD, et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58(6):931\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2008.02.004.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2419_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1177\/1359105310387954","volume":"16","author":"EF Williams","year":"2011","unstructured":"Williams EF, Gannon K, Soon K. The experiences of young people with epidermolysis bullosa simplex: a qualitative study. J Health Psychol. 2011;16(5):701\u201310. https:\/\/doi.org\/10.1177\/1359105310387954.","journal-title":"J Health Psychol"},{"issue":"4","key":"2419_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10880-010-9205-4","volume":"17","author":"F Margari","year":"2010","unstructured":"Margari F, Lecce PA, Santamato W, et al. Psychiatric symptoms and quality of life in patients affected by epidermolysis bullosa. J Clin Psychol Med Settings. 2010;17(4):333\u20139. https:\/\/doi.org\/10.1007\/s10880-010-9205-4.","journal-title":"J Clin Psychol Med Settings"},{"issue":"3","key":"2419_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/erp.10.28","volume":"10","author":"C Pagliarello","year":"2010","unstructured":"Pagliarello C, Tabolli S. Factors affecting quality of life in epidermolysis bullosa. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):329\u201338. https:\/\/doi.org\/10.1586\/erp.10.28.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"8","key":"2419_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1046\/j.1365-2230.2002.01121.x","volume":"27","author":"HM Horn","year":"2002","unstructured":"Horn HM, Tidman MJ. Quality of life in epidermolysis bullosa. Clin Exp Dermatol. 2002;27(8):707\u201310. https:\/\/doi.org\/10.1046\/j.1365-2230.2002.01121.x.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"2419_CR6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","volume":"161","author":"JW Frew","year":"2009","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Brit J Dermatol (1951). 2009;161(6):1323\u201330. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09347.x.","journal-title":"Brit J Dermatol (1951)."},{"issue":"4","key":"2419_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1365-2133.2009.09306.x","volume":"161","author":"S Tabolli","year":"2009","unstructured":"Tabolli S, Sampogna F, Di Pietro C, et al. Quality of life in patients with epidermolysis bullosa. Brit J Dermatol (1951). 2009;161(4):869\u201377. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09306.x.","journal-title":"Brit J Dermatol (1951)."},{"key":"2419_CR8","unstructured":"MedlinePlus. Dystrophic epidermolysis bullosa. National Library of Medicine (US). https:\/\/medlineplus.gov\/genetics\/condition\/dystrophic-epidermolysis-bullosa."},{"key":"2419_CR9","unstructured":"Orphanet. Prevalence and incidence of rare diseases: bibliographic data. Orphanet Report Series: Rare diseases collection. 2022(1). https:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Prevalence_of_rare_diseases_by_alphabetical_list.pdf."},{"issue":"11","key":"2419_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"J-D Fine","year":"2016","unstructured":"Fine J-D. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry. JAMA Dermatol (Chicago, IL). 2016;152(11):1231\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2473.","journal-title":"JAMA Dermatol (Chicago, IL)"},{"issue":"4","key":"2419_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Brit J Dermatol (1951). 2020;183(4):614\u201327. https:\/\/doi.org\/10.1111\/bjd.18921.","journal-title":"Brit J Dermatol (1951)."},{"issue":"1","key":"2419_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12916-014-0178-2","volume":"12","author":"KR Goldschneider","year":"2014","unstructured":"Goldschneider KR, Good J, Harrop E, et al. Pain care for patients with epidermolysis bullosa: best care practice guidelines. BMC Med. 2014;12(1):178\u2013178. https:\/\/doi.org\/10.1186\/s12916-014-0178-2.","journal-title":"BMC Med"},{"issue":"1","key":"2419_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13023-019-1086-5","volume":"14","author":"K Martin","year":"2019","unstructured":"Martin K, Geuens S, Asche JK, et al. Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines. Orphanet J Rare Dis. 2019;14(1):133\u2013133. https:\/\/doi.org\/10.1186\/s13023-019-1086-5.","journal-title":"Orphanet J Rare Dis"},{"key":"2419_CR14","volume-title":"Best practice guidelines for skin and wound care in epidermolysis bullosa. An international consensus","author":"J Denyer","year":"2017","unstructured":"Denyer J, Pillay E, Clapham J. Best practice guidelines for skin and wound care in epidermolysis bullosa. An international consensus. London: Wounds International; 2017."},{"issue":"1","key":"2419_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/bjd.14104","volume":"174","author":"JE Mellerio","year":"2016","unstructured":"Mellerio JE, Robertson SJ, Bernardis C, et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Brit J Dermatol (1951). 2016;174(1):56\u201367. https:\/\/doi.org\/10.1111\/bjd.14104.","journal-title":"Brit J Dermatol (1951)."},{"issue":"3","key":"2419_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaad.2009.03.052","volume":"61","author":"J-D Fine","year":"2009","unstructured":"Fine J-D, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa part I. Epithelial associated tissues. J Am Acad Dermatol. 2009;61(3):367\u201384. https:\/\/doi.org\/10.1016\/j.jaad.2009.03.052.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2419_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jaad.2009.03.053","volume":"61","author":"J-D Fine","year":"2009","unstructured":"Fine J-D, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009;61(3):387\u2013402; quiz 403\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2009.03.053.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2419_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1365-2230.2004.01428.x","volume":"29","author":"JD Fine","year":"2004","unstructured":"Fine JD, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol. 2004;29(2):122\u20137. https:\/\/doi.org\/10.1111\/j.1365-2230.2004.01428.x.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"2419_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/1049732308315110","volume":"18","author":"C van Scheppingen","year":"2008","unstructured":"van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis KGB, Jonkman MF. The main problems of parents of a child with epidermolysis bullosa. Qual Health Res. 2008;18(4):545\u201356. https:\/\/doi.org\/10.1177\/1049732308315110.","journal-title":"Qual Health Res"},{"issue":"6","key":"2419_CR20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/1049732311400431","volume":"21","author":"E Dures","year":"2011","unstructured":"Dures E, Morris M, Gleeson K, Rumsey N. The psychosocial impact of epidermolysis bullosa. Qual Health Res. 2011;21(6):771\u201382. https:\/\/doi.org\/10.1177\/1049732311400431.","journal-title":"Qual Health Res"},{"issue":"11","key":"2419_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.12968\/jowc.2012.21.11.528","volume":"21","author":"T Adni","year":"2012","unstructured":"Adni T, Martin K, Mudge E. The psychosocial impact of chronic wounds on patients with severe epidermolysis bullosa. J Wound Care. 2012;21(11):528\u201338. https:\/\/doi.org\/10.12968\/jowc.2012.21.11.528.","journal-title":"J Wound Care"},{"issue":"4","key":"2419_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2340\/00015555-1758","volume":"94","author":"WY Yuen","year":"2014","unstructured":"Yuen WY, Frew JW, Veerman K, van den Heuvel ER, Murrell DF, Jonkman MF. Health-related Quality of Life in Epidermolysis Bullosa: validation of the Dutch QOLEB Questionnaire and Assessment in the Dutch Population. Acta Derm Venereol. 2014;94(4):442\u20137. https:\/\/doi.org\/10.2340\/00015555-1758.","journal-title":"Acta Derm Venereol"},{"issue":"Suppl 1","key":"2419_CR23","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1007\/s10198-016-0783-4","volume":"17","author":"A Angelis","year":"2016","unstructured":"Angelis A, Kanavos P, L\u00f3pez-Bastida J, et al. Social\/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur J Health Econ. 2016;17(Suppl 1):S31\u201342. https:\/\/doi.org\/10.1007\/s10198-016-0783-4.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"2419_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.healthpol.2012.08.001","volume":"108","author":"R Linertov\u00e1","year":"2012","unstructured":"Linertov\u00e1 R, Serrano-Aguilar P, Posada-de-la-Paz M, et al. Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study Article. Health Policy. 2012;108(1):19\u201326. https:\/\/doi.org\/10.1016\/j.healthpol.2012.08.001.","journal-title":"Health Policy"},{"issue":"7","key":"2419_CR25","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","volume":"119","author":"A Angelis","year":"2015","unstructured":"Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119(7):964\u201379. https:\/\/doi.org\/10.1016\/j.healthpol.2014.12.016.","journal-title":"Health Policy"},{"key":"2419_CR26","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"1987","unstructured":"Drummond M, O\u2019Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1987."},{"key":"2419_CR27","volume-title":"Country indexes and weights. International Monetary Fund (IMF) data","author":"IMF","year":"2021","unstructured":"IMF. Country indexes and weights. International Monetary Fund (IMF) data. Washington, DC: IMF; 2021."},{"issue":"4","key":"2419_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/gps.353","volume":"16","author":"D McDaid","year":"2001","unstructured":"McDaid D. Estimating the costs of informal care for people with Alzheimer\u2019s disease: methodological and practical challenges. Int J Geriatr Psychiatry. 2001;16(4):400\u20135. https:\/\/doi.org\/10.1002\/gps.353.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"2419_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10198-003-0189-y","volume":"5","author":"B van den Berg","year":"2004","unstructured":"van den Berg B, Brouwer WBF, Koopmanschap MA. Economic valuation of informal care: an overview of methods and applications. Eur J Health Econ. 2004;5(1):36\u201345. https:\/\/doi.org\/10.1007\/s10198-003-0189-y.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"2419_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2307\/3349801","volume":"60","author":"TA Hodgson","year":"1982","unstructured":"Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60(3):429\u201362. https:\/\/doi.org\/10.2307\/3349801.","journal-title":"Milbank Mem Fund Q Health Soc"},{"issue":"1","key":"2419_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy (Amsterdam). 1996;37(1):53\u201372. https:\/\/doi.org\/10.1016\/0168-8510(96)00822-6.","journal-title":"Health Policy (Amsterdam)"},{"key":"2419_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/09638288809164103","volume":"10","author":"C Collin","year":"1988","unstructured":"Collin C, Wade D, Davies S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud. 1988;10:61\u20133.","journal-title":"Int Disabil Stud"},{"key":"2419_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1017\/S0714980800012484","volume":"19","author":"R H\u00e9bert","year":"2000","unstructured":"H\u00e9bert R, Bravo G, Pr\u00e9ville M. Reliability, validity and reference values of the Zarit Burden interview for assessing informal caregivers of community-dwelling older persons with dementia. Can J Aging La Revue canadienne du vieillissement. 2000;19:494\u2013507.","journal-title":"Can J Aging La Revue canadienne du vieillissement"},{"key":"2419_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-reported population health: an international perspective based on EQ-5D","author":"A Szende","year":"2014","unstructured":"Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Cham: Springer Open; 2014."},{"issue":"9","key":"2419_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10198-014-0638-9","volume":"16","author":"Y Yang","year":"2015","unstructured":"Yang Y, Brazier J, Longworth L. EQ-5D in skin conditions: an assessment of validity and responsiveness. Eur J Health Econ. 2015;16(9):927\u201339. https:\/\/doi.org\/10.1007\/s10198-014-0638-9.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"2419_CR36","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/09546634.2020.1800571","volume":"33","author":"Z Yang","year":"2022","unstructured":"Yang Z, Li S, Wang X, Chen G. Health state utility values derived from EQ-5D in psoriatic patients: a systematic review and meta-analysis. J Dermatol Treat. 2022;33(2):1029\u201336. https:\/\/doi.org\/10.1080\/09546634.2020.1800571.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"2419_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"AL Bruckner","year":"2020","unstructured":"Bruckner AL, Losow M, Wisk J, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1\u20131. https:\/\/doi.org\/10.1186\/s13023-019-1279-y.","journal-title":"Orphanet J Rare Dis"},{"key":"2419_CR38","unstructured":"Mellerio JE. OP20 PEBLES. Acta Derm Venereol. p. 9, 2020. https:\/\/www.medicaljournals.se\/acta\/content_files\/files\/pdf\/100\/220\/Suppl220.pdf."},{"key":"2419_CR39","unstructured":"Pillay EI, Jeffs E, Bisquera A, et al. P77 treatment costs for individuals with recessive dystrophic epidermolysis bullosa (RDEB): findings of the pebles study. Acta Derm Venereol. p. 58. 2020. https:\/\/www.medicaljournals.se\/acta\/content_files\/files\/pdf\/100\/220\/Suppl220.pdf."},{"issue":"8","key":"2419_CR40","doi-asserted-by":"publisher","first-page":"adv00116-2","DOI":"10.2340\/00015555-3456","volume":"100","author":"D Flannery","year":"2020","unstructured":"Flannery D, Doyle C, Hickey S, Aherne F, Kennan A. Direct costs of epidermolysis bullosa by disease severity. Acta Dermato Venereol. 2020;100(8):adv00116-2. https:\/\/doi.org\/10.2340\/00015555-3456.","journal-title":"Acta Dermato Venereol"},{"issue":"1","key":"2419_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1017\/S0266462313000640","volume":"30","author":"D Tordrup","year":"2014","unstructured":"Tordrup D, Mossman J, Kanavos P. Responsiveness of the EQ-5D to clinical change: is the patient experience adequately represented? Int J Technol Assess Health Care. 2014;30(1):10\u20139.","journal-title":"Int J Technol Assess Health Care"},{"key":"2419_CR42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/CEOR.S44866","volume":"5","author":"BR Lensberg","year":"2013","unstructured":"Lensberg BR, Drummond MF, Danchenko N, Despi\u00e9gel N, Fran\u00e7ois C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. ClinicoEcon Outcomes Res. 2013;5:565\u201373. https:\/\/doi.org\/10.2147\/CEOR.S44866.","journal-title":"ClinicoEcon Outcomes Res"},{"issue":"1 Part 2","key":"2419_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-199813010-00001","volume":"13","author":"B Liljas","year":"1998","unstructured":"Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998;13(1 Part 2):1\u20137. https:\/\/doi.org\/10.2165\/00019053-199813010-00001.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"2419_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1177\/070674379904400505","volume":"44","author":"R Goeree","year":"1999","unstructured":"Goeree R, O\u2019Brien BJ, Blackhouse G, Agro K, Goering P. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. Can J Psychiatry. 1999;44(5):455\u201363. https:\/\/doi.org\/10.1177\/070674379904400505.","journal-title":"Can J Psychiatry"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02419-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T17:06:41Z","timestamp":1662484001000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02419-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2419"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02419-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original study protocol was submitted to the London School of Economics (LSE) Research Ethics Committee and received an exemption. All patients and caregivers were informed about the study\u2019s objective and data confidentiality arrangements and were then asked to indicate their understanding of the study conditions and their agreement to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JEM has undertaken paid consultancy for Krystal Biotech.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}